Cancer immunotherapy drugs known as immune checkpoint inhibitors (ICIs) can be miracle drugs for cancer patients, curing some and turning deadly disease into a manageable chronic condition in others. But these drugs work for only a subset of patients, with few indications why—a knowledge gap that has detrimental effects on patient prognosis, clinical trial recruitment and research that could lead to new therapies.
A new artificial intelligence model called COMPASS, developed by Harvard Medical School researchers and their colleagues, improves prediction of which patients are most likely to respond to ICIs...
Read More
Recent Comments